4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-004024
Options or other derivatives
- CHIEF SCIENTIFIC OFFICER acquired 185,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-02-13 | Grant or award : show line 1 in the form Stock Option (right to buy) | +185,000 | 185,000 | D |
Loading xslF345X05/form4-02162024_020217.xml…